pocketful logo light
pocketful logo light
Venus Remedies Ltd logo

Venus Remedies Ltd

NSE: VENUSREM BSE: 526953

₹1616.30

(0.49%)

Fri, 18 Sept 2026, 06:02 am

mtf coin illustrationMTF 5x

Venus Remedies Share Price Live Chart

1 Day

(0.49%)

No Result Found

Summary

  • Market Cap (in Cr)

    1714.78

  • Net Profit (in Cr)

    45.31

  • P/B

    0.71

  • Sector P/E

    33.76

  • P/E

    8.84

  • EV/EBITDA

    3.41

  • Debt/Equity (Industry)

    0.47

  • Interest Cover (Industry)

    5.19

  • ROCE (Industry)

    14.14

  • RONW (Industry)

    11.70

  • ROE

    7.16

  • ROCE

    10.93

  • Debt/Equity

    0.04

  • EPS (TTM)

    76.90

  • Dividend Yield

    0

  • Book Value

    496.56

  • Interest Cover

    862.13

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters41.7641.7641.7641.7641.76
FII2.802.261.862.241.34
DII1.201.030.750.110
Public54.2454.9655.6355.8956.90
Government00000

Read More

Technical Analysis

RSI

43.83

MACD

-26.23

50 DMA

1657.40

200 DMA

1169.05

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2507.532083.931873.771660.331450.171236.73813.13
Fibonacci2083.931922.121822.151660.331498.521398.551236.73
Camarilla1780.091741.261702.431660.331624.771585.941547.11

Pivots Level: Classic

R3

+847.20

2507.53

R2

+423.60

2083.93

R1

+213.43

1873.77

1660.33
1660.33
Pivot Point
LTP: 1575

S1

-210.17

1450.17

S2

-423.60

1236.73

S3

-847.20

813.13

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1594.41

  • 20-EMA

    1619.85

  • 30-EMA

    1630.35

  • 50-EMA

    1619.13

  • 100-EMA

    1498.63

  • 200-EMA

    1249.19

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
26 May 2026board-meetingsAccounts, Final Dividend, AGM
29 Jan 2026board-meetingsQuarterly Results
10 Nov 2025board-meetingsQuarterly Results
08 Jul 2025agm
21 Aug 2024agm
13 Aug 2024agmAnnual General Meeting17 Sept 2024
17 Jul 2023agmAnnual General Meeting18 Aug 2023
15 Jul 2023agm
25 Jul 2022agm
11 Jul 2022agmAnnual General Meeting17 Aug 2022

Read More

Peer Comparison

Venus Remedies Ltd logo

Venus Remedies Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Read More

Venus Remedies Ltd About

Venus Remedies is one of the handful player in pharmaceutical sector to launch injectables globally. It has world-class manufacturing facilities in Panchkula and Baddi (in India), and research and development centre under the name of Venus Medicine Research Centre.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1989

Headquarters

CEO

Pawan Chaudhary

Employees

Contact

Website icon

Website

http://www.venusremedies.com

Email icon

Email

investorgrievance@venusremedies.com; complianceoff

Phone icon

Phone

Location icon

Location

S C No 857 Cabin No 10 2nd Flr, N A C Manimajra, Chandigarh, Chandigarh, 160101

Read More

Venus Remedies Ltd Company History

YearHistory
2019
  • Venus announces deal with Cipla for its patented product Elores for Indian Territory.
2021
  • Venus Remedies launched its full-fledged Consumer Healthcare Division.
  • Venus Remedies Limited has been selected for Production Linked Incentive Scheme (PLI) of the Government of India.
2022
  • Venus Remedies won WHO Good Distribution Practices (GDP) certification for quality services across entire supply chain.
  • Venus remedies wins ambitionbox best places to work award.
  • Venus Remedies Limited has been Great Place to Work Certified.
2023
  • Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering ''Organ-on-a-Chip'' Research Model.
  • Venus Remedies Limited Honored with Best Working Conditions Award 2022.
  • Venus Remedies launched flagship R&D drug Elores in Oman.
  • Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from four more countries.
  • Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities.
  • Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.
2024
  • Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product.
  • Venus Remedies awarded with Rs.2.50cr as the remaining part of its first incentive under PLi scheme.
  • Venus Remedies awarded its first incentive of Rs.7.50 crores under PLI scheme.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
PRADEEP KUMAR JAINbulkSell135966422.7730 May 2025
SAMYAK ENTERPRISESbulkBuy90000292.721 Mar 2025
MC JAIN INFOSERVICES PRIVATE LIMITEDbulkSell90000292.721 Mar 2025
CRONY VYAPAR PVT LTDbulkBuy75190356.9106 Feb 2025
PARTH INFIN BROKERS PVT LTDbulkSell114490353.8806 Feb 2025
PARTH INFIN BROKERS PVT LTDbulkBuy125195354.8306 Feb 2025
CRONY VYAPAR PVT LTDbulkSell50190352.606 Feb 2025
GRAVITON RESEARCH CAPITAL LLPbulkBuy68957376.5613 Jun 2024
GRAVITON RESEARCH CAPITAL LLPbulkSell68957377.2113 Jun 2024
SOCIETE GENERALEbulkBuy66838380.2524 Jan 2024

Read More

Venus Remedies Ltd News

Venus Remedies AGM: Dividend, Board Changes

Venus Remedies Limited convenes its 37th AGM on August 20, 2026, to approve a ₹10 dividend and appoint new directors. The meeting also seeks ratification of cost auditor fees and amendments to the MOA.

27 Jul 2026

companies

Venus Remedies Q1 net profit rises 118% YoY

Venus Remedies reported a consolidated net profit of ₹22.97 crore for Q1FY26, up from ₹9.60 crore in the year-ago period. Revenue from operations increased to ₹178.86 crore.

20 Jul 2026

companies

Venus Remedies declares ₹10 dividend

Venus Remedies Limited has announced a final dividend of ₹10 per share for FY26. The company set August 7, 2026, as the record date for determining shareholder eligibility.

03 Jul 2026

companies

Venus Remedies FY26 net profit rises 89% to ₹102.78 crore

Venus Remedies reported a consolidated net profit of ₹102.78 crore for FY26, up from ₹45.31 crore in the previous year. The board recommended a final dividend of ₹10 per share and scheduled the AGM for August 20, 2026.

26 May 2026

companies

Venus Remedies Gets Saudi FDA Nod for Plerixafor

Venus Remedies secures Saudi FDA approval for Plerixafor, marking its first global marketing authorization for this specialty cancer treatment.

22 May 2026

companies

Read More

Frequently Asked Questions

  • 1.What is the stock price of Venus Remedies Ltd?

    As of 18/09/2026 at 11:32 AM, Venus Remedies Ltd shares are trading at ₹1616.30.

  • 2.What is the market cap. of Venus Remedies Ltd?

    As of 18/09/2026, the market capitalization of Venus Remedies Ltd is ₹2,181.83 crore.

  • 3.When was Venus Remedies Ltd founded?

    Venus Remedies Ltd was founded in 1989.

  • 4.What are the P/E and P/B ratios of Venus Remedies Ltd?

    As of 18/09/2026, Venus Remedies Ltd has a P/E ratio of 18.60 and a P/B ratio of 0.71.

  • 5.How can I buy shares of Venus Remedies Ltd?

    You can buy shares of Venus Remedies Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Venus Remedies Ltd?

    As of March,2026, promoters hold 41.76% in Venus Remedies Ltd, while FIIs, DIIs and public shareholders hold 2.80%, 1.20% and 54.24%, respectively.

  • 7.Does Venus Remedies Ltd pay dividends?

    Yes, Venus Remedies Ltd pays dividends to eligible shareholders.

  • 8.What is the dividend yield of Venus Remedies Ltd?

    As of 18 September, 2026, the dividend yield of Venus Remedies Ltd stands at 0.61%.

  • 9.What are the latest financial results of Venus Remedies Ltd?

    For January,2024, Venus Remedies Ltd reported revenue of ₹648.00 crore and a net profit of ₹45.32 crore.

  • 10.What is the Stock symbol of Venus Remedies Ltd?

    VENUSREM is the stock symbol of Venus Remedies Ltd.

  • 11.Who is the CEO of Venus Remedies Ltd?

    The CEO of Venus Remedies Ltd is Pawan Chaudhary.

Open Your Free Demat Account

Enter your phone number